{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:23:06Z","timestamp":1785435786526,"version":"3.56.0"},"reference-count":48,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"\u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy","award":["PCD 283\/18\/12.01.2026"],"award-info":[{"award-number":["PCD 283\/18\/12.01.2026"]}]},{"award":["PCD 283\/18\/12.01.2026"],"award-info":[{"award-number":["PCD 283\/18\/12.01.2026"]}],"id":[{"id":"https:\/\/ror.org\/051h0cw83","id-type":"ROR","asserted-by":"publisher"}]},{"name":"European Union\u2014NextGenerationEU","award":["760072\/23.05.2023"],"award-info":[{"award-number":["760072\/23.05.2023"]}]},{"name":"European Union\u2014NextGenerationEU","award":["CF 16\/15.11.2022"],"award-info":[{"award-number":["CF 16\/15.11.2022"]}]},{"name":"Romanian Ministry of Research, Innovation and Digitalization"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: The role of neoadjuvant or perioperative treatment in anatomically resectable pancreatic ductal adenocarcinoma (PDAC) remains intensely debated, in part because prior evidence syntheses have often pooled resectable and borderline-resectable disease. We aim to evaluate the efficacy and safety of neoadjuvant or perioperative treatment versus upfront surgery in trial-defined resectable PDAC using randomized evidence only. Materials and Methods: We performed a systematic review and meta-analysis of parallel-group randomized controlled trials comparing neoadjuvant therapy with upfront surgery in adults with resectable PDAC. PubMed, CENTRAL, Scopus, and Clarivate Web of Science were searched from inception until 30 November 2025. Mixed resectable- and borderline-resectable trials were included only when outcomes for the resectable subgroup were extractable. The primary outcome was overall survival (OS), analyzed on an intention-to-treat basis. Secondary outcomes included time-to-disease-event (TTDE) endpoints, resection rate, R0 resection, pathological node-negative (pN0) status, postoperative morbidity and mortality, and grade \u22653 adverse events. The review protocol was prospectively registered in PROSPERO (CRD420251243805). Results: Eight randomized controlled trials enrolling 1395 patients, including 1184 patients with resectable PDAC, met the eligibility criteria. Overall survival was available for six trials (seven comparisons totaling 1066 randomized patients) and was not significantly different between neoadjuvant treatment and upfront surgery (HR 0.80, 95% CI 0.59\u20131.08). TTDE was likewise not significantly different between strategies (HR 0.80, 95% CI 0.58\u20131.11). Neoadjuvant treatment reduced the likelihood of proceeding to resection (RR 0.90, 95% CI 0.85\u20130.95), while R0 resection and pN0 rates were numerically but not significantly higher among the resected patients. Postoperative morbidity and mortality were comparable between groups. Exploratory analyses suggested favorable survival estimates in trials with higher neoadjuvant treatment deliverability and completion. Conclusions: In trial-defined resectable PDAC, current randomized evidence does not demonstrate a universal survival advantage for neoadjuvant treatment over upfront surgery. Exploratory trial-level analyses suggested that higher neoadjuvant treatment deliverability and completion were associated with more favorable survival estimates. These findings support a selective, individualized rather than routine use of preoperative strategies in resectable PDAC.<\/jats:p>","DOI":"10.3390\/medicina62061049","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T12:09:07Z","timestamp":1779970147000},"page":"1049","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant Treatment Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma\u2014A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5230-6680","authenticated-orcid":false,"given":"Traian Adrian","family":"Du\u0219e","sequence":"first","affiliation":[{"name":"Department of Surgery\u2014Surgery III, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, Croitorilor Street, No. 19\u201321, 400162 Cluj-Napoca, Romania"},{"name":"Department of Surgery, \u201cOctavian Fodor\u201d Regional Institute of Gastroenterology and Hepatology, Croitorilor Street, No. 19\u201321, 400162 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0126-6428","authenticated-orcid":false,"given":"Andra","family":"Ciocan","sequence":"additional","affiliation":[{"name":"Department of Surgery\u2014Surgery III, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, Croitorilor Street, No. 19\u201321, 400162 Cluj-Napoca, Romania"},{"name":"Department of Surgery, \u201cOctavian Fodor\u201d Regional Institute of Gastroenterology and Hepatology, Croitorilor Street, No. 19\u201321, 400162 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denisa Elena","family":"Tiburca","sequence":"additional","affiliation":[{"name":"Bihor County Clinical Emergency Hospital, 410167 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0007-8962","authenticated-orcid":false,"given":"Vlad Dumitru","family":"Brata","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, \u201cOctavian Fodor\u201d Regional Institute of Gastroenterology and Hepatology, Croitorilor Street, No. 19\u201321, 400162 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7968-908X","authenticated-orcid":false,"given":"Radu","family":"Vidra","sequence":"additional","affiliation":[{"name":"MEDFUTURE Biomedical Research Institute, Department of Personalized Medicine and Rare Diseases, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400347 Cluj-Napoca, Romania"},{"name":"Department of Oncology, \u201cOctavian Fodor\u201d Regional Institute of Gastroenterology and Hepatology, Croitorilor Street, No. 19\u201321, 400162 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florin Vasile","family":"Zaharie","sequence":"additional","affiliation":[{"name":"Department of Surgery\u2014Surgery III, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, Croitorilor Street, No. 19\u201321, 400162 Cluj-Napoca, Romania"},{"name":"Department of Surgery, \u201cOctavian Fodor\u201d Regional Institute of Gastroenterology and Hepatology, Croitorilor Street, No. 19\u201321, 400162 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrada","family":"Seicean","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, \u201cOctavian Fodor\u201d Regional Institute of Gastroenterology and Hepatology, Croitorilor Street, No. 19\u201321, 400162 Cluj-Napoca, Romania"},{"name":"Department of Gastroenterology, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, Croitorilor Street, No. 19\u201321, 400162 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciprian","family":"Brisc","sequence":"additional","affiliation":[{"name":"Department of Medical Disciplines, University of Oradea, 410073 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u0103lin","family":"Popa","sequence":"additional","affiliation":[{"name":"Department of Surgery\u2014Surgery III, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, Croitorilor Street, No. 19\u201321, 400162 Cluj-Napoca, Romania"},{"name":"Department of Surgery, \u201cOctavian Fodor\u201d Regional Institute of Gastroenterology and Hepatology, Croitorilor Street, No. 19\u201321, 400162 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Moi\u0219","sequence":"additional","affiliation":[{"name":"Department of Surgery, \u201cOctavian Fodor\u201d Regional Institute of Gastroenterology and Hepatology, Croitorilor Street, No. 19\u201321, 400162 Cluj-Napoca, Romania"},{"name":"Department of Surgical Disciplines, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, Croitorilor Street, No. 19\u201321, 400162 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip Cristian","family":"Tocoian","sequence":"additional","affiliation":[{"name":"Department of Surgery\u2014Surgery III, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, Croitorilor Street, No. 19\u201321, 400162 Cluj-Napoca, Romania"},{"name":"Department of Surgery, \u201cOctavian Fodor\u201d Regional Institute of Gastroenterology and Hepatology, Croitorilor Street, No. 19\u201321, 400162 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadim","family":"Al Hajjar","sequence":"additional","affiliation":[{"name":"Department of Surgery\u2014Surgery III, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, Croitorilor Street, No. 19\u201321, 400162 Cluj-Napoca, Romania"},{"name":"Department of Surgery, \u201cOctavian Fodor\u201d Regional Institute of Gastroenterology and Hepatology, Croitorilor Street, No. 19\u201321, 400162 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Li, T., Lin, C., and Wang, W. (2025). Global, regional, and national burden of pancreatic cancer from 1990 to 2021, its attributable risk factors, and projections to 2050: A systematic analysis of the global burden of disease study 2021. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-13597-z"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/SLA.0000000000002234","article-title":"Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma","volume":"267","author":"Groot","year":"2018","journal-title":"Ann. Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1097\/SLA.0000000000002734","article-title":"Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma","volume":"269","author":"Groot","year":"2019","journal-title":"Ann. Surg."},{"key":"ref_5","unstructured":"(2026). Pancreatic Adenocarcinoma (Version 1.2026), National Comprehensive Cancer Network (NCCN). Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?id=1455."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1200\/JCO.19.00946","article-title":"Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update","volume":"37","author":"Khorana","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S0140-6736(25)00261-2","article-title":"Pancreatic cancer","volume":"405","author":"Stoop","year":"2025","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/SLA.0000000000000378","article-title":"Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer","volume":"260","author":"Merkow","year":"2014","journal-title":"Ann. Surg."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/SLA.0000000000005126","article-title":"Neoadjuvant Therapy for Resectable Pancreatic Cancer: A New Standard of Care. Pooled Data From 3 Randomized Controlled Trials","volume":"274","author":"Birrer","year":"2021","journal-title":"Ann. Surg."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Janssen, Q.P., O\u2019Reilly, E.M., van Eijck, C.H.J., and Groot Koerkamp, B. (2020). Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00041"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"105826","DOI":"10.1016\/j.esmoop.2025.105826","article-title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer","volume":"10","author":"Tai","year":"2025","journal-title":"ESMO Open"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial","volume":"40","author":"Versteijne","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/SLA.0000000000006730","article-title":"Neoadjuvant Chemotherapy With Gemcitabine and S-1 Versus Upfront Surgery for Resectable Pancreatic Cancer: Results of the Randomized Phase II\/III Prep-02\/JSAP05 Trial","volume":"283","author":"Unno","year":"2026","journal-title":"Ann. Surg."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"109872","DOI":"10.1016\/j.surg.2025.109872","article-title":"Neoadjuvant therapy versus upfront surgery for resectable pancreatic cancer: Updated systematic review, individual-patient-data meta-analysis and trial sequential analysis of randomized controlled trials","volume":"193","author":"Tan","year":"2025","journal-title":"Surgery"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Huan, L., Yu, F., Cao, D., Zhou, H., Qin, M., and Cao, Y. (2024). Comparison of neoadjuvant treatment and surgery first for resectable or borderline resectable pancreatic carcinoma: A systematic review and network meta-analysis of randomized controlled trials. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0295983"},{"key":"ref_16","unstructured":"Higgins, J.P.T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., and Welch, V.A. (2023). Cochrane Handbook for Systematic Reviews of Interventions, Version 6.4 (Updated August 2023), Cochrane. Available online: https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Schwarz, L., Vernerey, D., Bachet, J.B., Tuech, J.J., Portales, F., Michel, P., and Cunha, A.S. (2018). Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy\u2014A multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study). BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4663-4"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/jjco\/hyy190","article-title":"Randomized phase II\/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02\/JSAP05)","volume":"49","author":"Motoi","year":"2019","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE Working Group. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Guyot, P., Ades, A.E., Ouwens, M.J., and Welton, N.J. (2012). Enhanced secondary analysis of survival data: Reconstructing the data from published Kaplan-Meier survival curves. BMC Med. Res. Methodol., 12.","DOI":"10.1186\/1471-2288-12-9"},{"key":"ref_25","unstructured":"(2026, January 12). PlotDigitizer. Version 3.1.6. Available online: https:\/\/plotdigitizer.com."},{"key":"ref_26","unstructured":"(2026, January 12). IPDfromKM. Version 1.2.4.0. Available online: https:\/\/biostatistics.mdanderson.org\/shinyapps\/IPDfromKM."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"IntHout, J., Ioannidis, J.P., and Borm, G.F. (2014). The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med. Res. Methodol., 14.","DOI":"10.1186\/1471-2288-14-25"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: A practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid. Based Ment. Health"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting Meta-Analyses in R with the metafor Package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J. Stat. Softw."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Harrer, M., Cuijpers, P., Furukawa, T., and Ebert, D. (2021). Doing Meta-Analysis with R: A Hands-On Guide, Chapman and Hall\/CRC. [1st ed.].","DOI":"10.1201\/9781003107347"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1016\/j.ccell.2025.09.009","article-title":"Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial","volume":"43","author":"Bai","year":"2025","journal-title":"Cancer Cell"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S2468-1253(23)00405-3","article-title":"Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): A multicentre, randomised, phase 2 trial","volume":"9","author":"Labori","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.annonc.2022.09.161","article-title":"Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group","volume":"34","author":"Seufferlein","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S2468-1253(18)30081-5","article-title":"Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): A randomised, open-label, phase 2-3 trial","volume":"3","author":"Reni","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s11605-015-2890-4","article-title":"Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which Failed to Achieve Accrual Targets","volume":"19","author":"Casadei","year":"2015","journal-title":"J. Gastrointest. Surg."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"43","DOI":"10.21294\/1814-4861-2025-24-4-43-53","article-title":"Immediate results of neoadjuvant chemotherapy with mFOLFIRINOX regimen in patients with resectable pancreatic cancer","volume":"24","author":"Vervekin","year":"2025","journal-title":"Sib. J. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejca.2021.10.023","article-title":"Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials","volume":"160","author":"Janssen","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Cloyd, J.M., Heh, V., Pawlik, T.M., Ejaz, A., Dillhoff, M., Tsung, A., Williams, T., Abushahin, L., Bridges, J.F.P., and Santry, H. (2020). Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials. J. Clin. Med., 9.","DOI":"10.3390\/jcm9041129"},{"key":"ref_40","first-page":"453","article-title":"Neoadjuvant therapy versus upfront surgery approach in resectable pancreatic cancer: A systematic review and meta-analysis","volume":"38","author":"Tanadi","year":"2025","journal-title":"Ann. Gastroenterol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e44570","DOI":"10.1097\/MD.0000000000044570","article-title":"Comparison of efficacy and safety between neoadjuvant therapy and surgical treatment for resectable pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials","volume":"104","author":"Zuo","year":"2025","journal-title":"Medicine"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11605-013-2412-1","article-title":"Treatment sequencing for resectable pancreatic cancer: Influence of early metastases and surgical complications on multimodality therapy completion and survival","volume":"18","author":"Tzeng","year":"2014","journal-title":"J. Gastrointest. Surg."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Oba, A., Ho, F., Bao, Q.R., Al-Musawi, M.H., Schulick, R.D., and Del Chiaro, M. (2020). Neoadjuvant Treatment in Pancreatic Cancer. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00245"},{"key":"ref_44","first-page":"579","article-title":"Neoadjuvant therapy for localized pancreatic cancer: A concept comes of age","volume":"12","author":"Sohal","year":"2014","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/bjs.5397","article-title":"Redefining the R1 resection in pancreatic cancer","volume":"93","author":"Verbeke","year":"2006","journal-title":"Br. J. Surg."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/S1470-2045(25)00363-8","article-title":"Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): A multicentre, open-label, phase 3 randomised trial","volume":"26","author":"Janssen","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"van Dam, J.L., Verkolf, E.M.M., Dekker, E.N., Bonsing, B.A., Bratlie, S.O., Brosens, L.A.A., Busch, O.R., van Driel, L.M.J.W., van Eijck, C.H.J., and Feshtali, S. (2023). Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): Study protocol for a multicenter randomized controlled trial. BMC Cancer, 23.","DOI":"10.1016\/j.annonc.2023.09.2632"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/SLA.0000000000004155","article-title":"Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine\/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma","volume":"272","author":"Ahmad","year":"2020","journal-title":"Ann. Surg."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/6\/1049\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T12:39:20Z","timestamp":1779971960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/6\/1049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":48,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["medicina62061049"],"URL":"https:\/\/doi.org\/10.3390\/medicina62061049","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]}}}